News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
GroPep Limited Changes Track From Psoriasis Drug To Asthma
December 14, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Following poor efficacy in preclinical testing of its T-cell peptide drug candidate in psoriasis models, Adelaide biopharma GroPep (ASX:GRO) will undertake a market feasibility assessment for use of the drug in asthma.
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
Australia
MORE ON THIS TOPIC
Drug Development
5 Second-Half Biopharma Milestones To Watch
July 7, 2025
·
8 min read
·
Tristan Manalac
Immuno-oncology
Four Therapies Hanging On in Troubled TIGIT Space
July 7, 2025
·
9 min read
·
Tristan Manalac
Immunology and inflammation
Late-Stage Stumble for Cosentyx Sets Novartis Back in Autoimmune Condition
July 3, 2025
·
2 min read
·
Tristan Manalac
Women’s Health
Organon’s Endometriosis Drug Discontinued After Failing To Improve Pain
July 2, 2025
·
1 min read
·
Annalee Armstrong
